Switching under selection: how CoREST controls endocrine therapy resistance in ER⁺ breast cancer

Nat Struct Mol Biol. 2022 Nov;29(11):1040-1042. doi: 10.1038/s41594-022-00858-9.

Authors

Brent Y Chick^{1

2}, Diana C Hargreaves³

Affiliations

¹ Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA.
² Biological Sciences Graduate Program, University of California, San Diego, La Jolla, CA, USA.
³ Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA. dhargreaves@salk.edu.

PMID: 36344845
DOI: 10.1038/s41594-022-00858-9

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Drug Resistance, Neoplasm
Neoplasms*
Tamoxifen*

Substances

Tamoxifen

Grants and funding